Heineken Queen

Ms. Heineken Queen

University of Michigan, Ann Arbor, Michigan, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
WDWeiwei Dai
Weiwei Dai
JSJianliang Shen
Jianliang Shen
JYJunrong Yan
Junrong Yan
ABAlex J. Bott
Alex J. Bott
SMSara Maimouni
Sara Maimouni
Wei-Xing ZongWei-Xing Zong
Wei-Xing Zong
Glutamine synthetase (GS) catalyzes de novo synthesis of glutamine that facilitates cancer cell growth. In the liver, GS functions next to the urea cycle to remove ammonia waste. As a dysregulated urea cycle is implicated in cancer development, the impact of GS’s ammonia clearance function has not been explored in cancer. Here, we show that oncogenic activation of β-catenin (encoded by CTNNB1) led to a decreased urea cycle and elevated ammonia waste burden. While β-catenin induced the expression of GS, which is thought to be cancer promoting, surprisingly, genetic ablation of hepatic GS accelerated the onset of liver tumors in several mouse models that involved β-catenin activation. Mechanistically, GS ablation exacerbated hyperammonemia and facilitated the production of glutamate-derived nonessential amino acids, which subsequently stimulated mechanistic target of rapamycin complex 1 (mTORC1). Pharmacological and genetic inhibition of mTORC1 and glutamic transaminases suppressed tumorigenesis facilitated by GS ablation. While patients with hepatocellular carcinoma, especially those with CTNNB1 mutations, have an overall defective urea cycle and increased expression of GS, there exists a subset of patients with low GS expression that is associated with mTORC1 hyperactivation. Therefore, GS-mediated ammonia clearance serves as a tumor-suppressing mechanism in livers that harbor β-catenin activation mutations and a compromised urea cycle.

19 March 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
BSBrian Song
Brian Song
HQHeineken Queen
Heineken Queen
SFSarah F. Ferris
Sarah F. Ferris
RMReliza McGinnis
Reliza McGinnis
CKChaitanya Karanam
Chaitanya Karanam
AGAnutosh Ganguly
Anutosh Ganguly
Histotripsy-focused ultrasound treatment gives rise to systemic antitumor immune responses. We investigated whether histotripsy effects on immunosuppressive tumor hypoxia were a potential mechanism for these immunostimulatory effects. Immunocompetent or CD8-deficient C57BL/6 mice with flank B16F10 or YUMM1.7 melanoma tumors underwent sham or subtotal histotripsy. Tumor growth, immune cell infiltration, and intratumoral hypoxia responses were examined using flow cytometry and fluorescence microscopy. Chemokine receptor CXCR3 and hypoxia-inducible factor-1α (HIF1α) were intercepted with antibodies and inhibitors to assess their roles in immune responses after histotripsy. Histotripsy-treated tumors exhibited rapid loss of intratumoral hypoxia and suppression of HIF1α and downstream prosurvival proteins. Histotripsy was followed by intratumoral upregulation of the CXCR3 ligand CXCL10 and CXCR3+/CD8+ T-cell infiltration. Tumor growth inhibition by histotripsy was significantly diminished in CD8-deficient mice and mice receiving anti-CXCR3 mAb. Post-histotripsy inhibition of hypoxia and tumor growth eventually receded in parallel with cessation of CD8+ T-cell influx, and pharmacologic HIF1α suppression with the MEK inhibitor trametinib substantially augmented the therapeutic effects of histotripsy. Transient abrogation of intratumoral hypoxia and HIF1α-associated hypoxia responses is mechanistically linked with intratumoral infiltration of activated CXCR3+/CD8+ T cells via CXCL10–CXCR3 engagement. These findings suggest that the immune effects of histotripsy may be regulated by hypoxia abrogation and that pharmacologic hypoxia abrogation could potentiate the immunotherapeutic effects of histotripsy.

27 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
PCPo-Chien Chou
Po-Chien Chou
SRSwati Rajput
Swati Rajput
XZXiaoyun Zhao
Xiaoyun Zhao
CPChadni Patel
Chadni Patel
DADanielle Albaciete
Danielle Albaciete
Estela JacintoEstela Jacinto
Estela Jacinto
Cells adjust to nutrient fluctuations to restore metabolic homeostasis. The mechanistic target of rapamycin (mTOR) complex 2 responds to nutrient levels and growth signals to phosphorylate protein kinases belonging to the AGC (Protein Kinases A,G,C) family such as Akt and PKC. Phosphorylation of these AGC kinases at their conserved hydrophobic motif (HM) site by mTORC2 enhances their activation and mediates the functions of mTORC2 in cell growth and metabolism. Another AGC kinase family member that is known to undergo increased phosphorylation at the homologous HM site (Ser380) is the p90 ribosomal S6 kinase (RSK). Phosphorylation at Ser380 is facilitated by the activation of the mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) in response to growth factor stimulation. Here, we demonstrate that optimal phosphorylation of RSK at this site requires an intact mTORC2. We also found that RSK is robustly phosphorylated at Ser380 upon nutrient withdrawal or inhibition of glycolysis, conditions that increase mTORC2 activation. However, pharmacological inhibition of mTOR did not abolish RSK phosphorylation at Ser380, indicating that mTOR catalytic activity is not required for this phosphorylation. Since RSK and SIN1β colocalize at the membrane during serum restimulation and acute glutamine withdrawal, mTORC2 could act as a scaffold to enhance RSK HM site phosphorylation. Among the known RSK substrates, the CCTβ subunit of the chaperonin containing TCP-1 (CCT) complex had defective phosphorylation in the absence of mTORC2. Our findings indicate that the mTORC2-mediated phosphorylation of the RSK HM site could confer RSK substrate specificity and reveal that RSK responds to nutrient fluctuations.

7 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
HQHeineken Queen
Heineken Queen
SFSarah Ferris
Sarah Ferris
CCClifford S. Cho
Clifford S. Cho
AGAnutosh Ganguly
Anutosh Ganguly
Background/Objective: Hepatocellular carcinoma (HCC) is an aggressive disease that is known to be resistant to conventional chemotherapy and radiotherapy. While surgical resection and transarterial therapy can improve overall survival, the biological aspects of HCC contribute to the complexity of its management and limit the effectiveness of current treatment options. The purpose of this scoping review is to identify the limitations of the currently available therapies for HCC and explore the emerging role that histotripsy could play in addressing these limitations, with the intent of informing the direction of future research and clinical management. Methods: The PRISMA checklist for scoping reviews was followed to structure this review, and a systematic search was conducted in the following online databases: PubMed/MEDLINE (National Library of Medicine), Embase (Elsevier), and Scopus (Elsevier). Results: The current evidence supports that histotripsy offers several key advantages that address the limitations of the current treatment strategies for HCC. Clinical trials have highlighted the ability of this technology to destroy solid tumors and induce remission with minimal side effects. In addition, current preclinical studies point to the potent immunostimulatory effects of histotripsy, including the induction of abscopal effects. This poses significant promise in treating tumor metastasis as well as improving clinical regimens by combining histotripsy with immunotherapy. Future research should aim to overcome the current limitations of histotripsy and enhance clinical outcomes for patients. This review examines existing treatments for HCC, emphasizing the promising potential of combining histotripsy with immunotherapy to target the metastatic and advanced stages of the disease.

18 December 2024 in Immunotherapy
Verified
Journal Article
Closed access
HQHeineken Queen
Heineken Queen
CCClifford S. Cho
Clifford S. Cho

30 July 2025 in Research Square
Verified
Preprint
Open access
PDF file
Michal A OlszewskiMichal A Olszewski
Michal A Olszewski
Hailong LiHailong Li
Hailong Li
RHRylan Hissong
Rylan Hissong
KGKristie Goughenour
Kristie Goughenour
YSYekateryna Sinitsyna
Yekateryna Sinitsyna
JXJintao Xu
Jintao Xu
Inflammatory brain damage is an important factor contributing to mortality or lasting neurological sequelae in CNS infections, such as cryptococcal meningoencephalitis (CM), but little is known about natural immunoregulatory mechanisms in the infected brain. Here we report that regulatory T cells (Tregs) are a central immunoregulatory component in CM. Tregs are present within the CNS in both human CM patients and in the experimental murine CM. Treg-depletion exacerbates Th1-driven brain inflammation and neurological symptoms, accelerating mortality, despite enhanced fungal clearance in mouse CM. Aligned brain NanoString, scRNA-seq, and flow cytometry analyses revealed that Tregs reduce brain inflammation, especially T-cell recruitment activation and differentiation, shielding the brain from neurological damage. The major CNS-Treg recruitment appears to be chemokine receptor CCR8-mediated, supporting the importance of the CCR8/CCL1 axis in Treg recruitment into the brain. Tregs in CM are major producers of anti-inflammatory IL-10 and the growth factor Amphiregulin (Areg), which is implicated in neuronal repair. IL-10 deletion in murine CM phenocopies Treg depletion. Areg deletion showed no survival effect; however, IFN-γ production by effector T cells in the brain was reduced, supporting Aregs as a potential internal regulator of Treg immunosuppressive function. Finally, a Treg-enhancing immunotherapy using low dose IL-2-immune complex treatment substantially improves mouse survival and neurological outcomes. Together, we identified that Tregs are crucial for neuronal protection in CM, predominantly via IL-10 production, the CCR8-CCL1 axis is an important CNS-Treg recruitment mechanism and Treg enhancement is a potential therapeutic strategy to mitigate immunopathology during CM, and possibly other forms of meningitis.